Cochrane · systematic review · CD007302
Vigabatrin add‐on therapy for drug‐resistant focal epilepsy
Bresnahan, R, Gianatsi, M, Maguire, MJ, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 42.9%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Vigabatrin compared to placebo for drug‐resistant focal epilepsy
Population: people (aged 10–64 years) with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
≥ 50% reduction in seizure frequency (ITT analysis) Duration of treatment (range): 16–36 weeks Vigabatrin vs placebo | RR 2.6 [1.87, 3.63] | 4 studies · 513 participants | Low Downgraded: risk of bias, imprecision |
Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks Vigabatrin vs placebo | RR 2.86 [1.25, 6.55] | 4 studies · 370 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects: ataxia Duration of treatment (range): 7–36 weeks Vigabatrin vs placebo | RR 2.76 [0.96, 7.94] | 7 studies · 481 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects: dizziness/light‐headedness Duration of treatment (range): 7–36 weeks Vigabatrin vs placebo | RR 1.74 [1.05, 2.87] | 9 studies · 709 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: fatigue Duration of treatment (range): 8–36 weeks Vigabatrin vs placebo | RR 1.65 [1.08, 2.51] | 9 studies · 709 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks Vigabatrin vs placebo | RR 1.53 [0.62, 3.76] | 2 studies · 357 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks Vigabatrin vs placebo | RR 1.64 [0.67, 4.02] | 5 studies · 430 participants | Very low Downgraded: risk of bias, imprecision |